- European AI Drug Discovery Attracting Tech Investor Betsby Mark Zipkin on Maggio 14, 2021 at 4:57 pm
Exscientia’s latest €434.9M ($525M) financing last month showed investors are still excited by efforts to use artificial intelligence to fuel drug discovery, with global tech investors often taking the lead. The Oxford, UK-based company Exscientia has one of the most mature artificial intelligence (AI)-focused drug discovery pipelines, alongside companies like BenevolentAI in the UK, and Aria Pharmaceuticals and Atomwise in the US. Earlier this week, Exscientia announced its third partnered program was heading to the clinic, a small molecule for psychotic symptoms resulting from Alzheimer’s disease. This is the second clinical asset from Exscientia’s neuroscience partnership with the Japanese firm Sumitomo Dainippon Pharma — the first went to clinical trials last year for the treatment of obsessive-compulsive disorder. Exscientia’s other clinical asset, a cancer immunotherapy developed with the German company Evotec, began phase I testing in April. Exscientia’s latest financing included a €186.4M ($225M) Series D led by the tech-focused SoftBank, which also pledged an additional €248.5M ($300M) equity commitment for use at the company’s discretion. Combined, The post European AI Drug Discovery Attracting Tech Investor Bets appeared first on Labiotech.eu.
- Fate offers glimpse at 'natural killer' cell therapy for leukemiaby Ben Fidler on Maggio 14, 2021 at 4:15 pm
The biotech's treatment is part of a wave of new treatments meant to mimic the effects of natural killer cell transplants in leukemia, though analysts remain skeptical.
- Biogen gene therapy misses goal in eye disease studyby Ned Pagliarulo on Maggio 14, 2021 at 3:15 pm
The results are a setback for Biogen, which spent $800 million two years ago to acquire the treatment's developer, Nightstar Therapeutics.
- Otonomy eyes clinical trial of hearing loss gene therapy with promising animal databy Angus Liu on Maggio 14, 2021 at 12:56 pm
Otonomy eyes clinical trial of hearing loss gene therapy with promising animal data aliu Fri, 05/14/2021 - 08:56
- Compass inks Trigr takeover to land clinical-phase bispecificby Nick Paul on Maggio 14, 2021 at 11:51 am
Compass inks Trigr takeover to land clinical-phase bispecific ntaylor Fri, 05/14/2021 - 07:51
- Kinnate, OrbiMed team up to target Chinese lung cancer marketby Nick Paul on Maggio 14, 2021 at 10:44 am
Kinnate, OrbiMed team up to target Chinese lung cancer market ntaylor Fri, 05/14/2021 - 06:44
- With a new CMO and phase 3 data to hand, Humanigen eyes COVID-19 drug emergency filing by Juneby Ben Adams on Maggio 14, 2021 at 8:22 am
With a new CMO and phase 3 data to hand, Humanigen eyes COVID-19 drug emergency filing by June badams Fri, 05/14/2021 - 04:22
- BioSpace Movers & Shakers, May 14on Maggio 14, 2021 at 12:00 am
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
- Philadelphia, Pacific Northwest See Surge in Biopharma Jobson Maggio 14, 2021 at 12:00 am
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here’s a look.
- Clearing Up a Misconception: COVID-19 Vaccines and Infertility/Pregnancy Losson Maggio 14, 2021 at 12:00 am
A study, published recently in the New England Journal of Medicine, demonstrated no obvious safety signals among pregnant persons who received the mRNA vaccines.
- PerkinElmer Picks Up Nexcelom for $260 Million to Expedite Drugs to Marketon Maggio 14, 2021 at 12:00 am
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
- Humanigen On the Cusp of Filing for Lenzilumab EUA in Hospitalized COVID-19 Patientson Maggio 14, 2021 at 12:00 am
Humanigen reported it had held a meeting with the FDA to discuss plans for filing an EUA for its lenzilumab for hospitalized, hypoxic COVID-19 patients by the end of May.
- Research Roundup: Neuronal Cell Death in Alzheimer’s and Moreon Maggio 14, 2021 at 12:00 am
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
- Report Highlights “Disinformation Dozen” Responsible for Online COVID-19 Vaccine Misinformationon Maggio 14, 2021 at 12:00 am
Overall, the researchers claim this “Disinformation Dozen” generate approximately 65% of the anti-vaccine misinformation on these platforms.
- Pfizer Commits to Bridging the Diversity Gap in Clinical Trialson Maggio 14, 2021 at 12:00 am
Pfizer’s clinical trials diversity report showed the disproportionate way the virus impacted minority communities in the U.S., increasing the calls for racial and ethnic diversity in clinical studies.
- Cellino Develops Scalable, Closed-Loop System for Autologous Stem Cell Manufacturingon Maggio 14, 2021 at 12:00 am
Cellino’s unique blend of lasers and machine learning is transforming the manufacture of autologous stem cell therapies from an inconsistent hand-crafted endeavor to a scalable, efficient, closed-loop, modern process.
- Interline Will Focus $92 Million Investment to Advance Precision Medicine Platformon Maggio 14, 2021 at 12:00 am
Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.
- Biopharma Job Market Booms in Singapore, N.C. and Marylandon Maggio 14, 2021 at 12:00 am
The help wanted signs are up across the biopharma industry. Companies are opening and expanding facilities, which is good news for job seekers.
- Biogen's Gene Therapy Strikes Out in Phase II/III Retinitis Pigmentosa Trialon Maggio 14, 2021 at 12:00 am
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
- Chutes & Ladders—Gossamer vet Salter-Cid dons CSO mantle at Flagship's new Pioneering Medicines unitby Fraiser Kansteiner on Maggio 13, 2021 at 6:10 pm
Chutes & Ladders—Gossamer vet Salter-Cid dons CSO mantle at Flagship's new Pioneering Medicines unit fkansteiner Thu, 05/13/2021 - 14:10
- Merck, with new breast cancer data, aims to rebound from FDA rejectionby Ben Fidler on Maggio 13, 2021 at 3:45 pm
Study results could address concerns raised by FDA advisers who recently voted against approval of Keytruda in patients with early-stage breast cancer.
- Heron, on third attempt, secures FDA approval for non-opioid painkillerby Kristin Jensen on Maggio 13, 2021 at 3:00 pm
The San Diego-based biotech's drug, which will now be sold as Zynrelef, had perviously been rejected by the agency in 2019 and 2020.
- NEA-backed Allay exits stealth with clinical pain data, plans to reduce need for opioidsby Nick Paul on Maggio 13, 2021 at 12:09 pm
NEA-backed Allay exits stealth with clinical pain data, plans to reduce need for opioids ntaylor Thu, 05/13/2021 - 08:09
- Autolus' CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS in small lymphoma trialby Nick Paul on Maggio 13, 2021 at 11:33 am
Autolus' CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS in small lymphoma trial ntaylor Thu, 05/13/2021 - 07:33
- How a genetic 'CopyCatcher' could open the door to CRISPR-based precision gene therapyby Angus Liu on Maggio 13, 2021 at 11:26 am
How a genetic 'CopyCatcher' could open the door to CRISPR-based precision gene therapy aliu Thu, 05/13/2021 - 07:26